Prothena Corporation PLC
NASDAQ:PRTA

Watchlist Manager
Prothena Corporation PLC Logo
Prothena Corporation PLC
NASDAQ:PRTA
Watchlist
Price: 10.32 USD -3.82% Market Closed
Market Cap: 555.5m USD

Prothena Corporation PLC
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Prothena Corporation PLC
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Prothena Corporation PLC
NASDAQ:PRTA
Net Income (Common)
-$280.5m
CAGR 3-Years
-21%
CAGR 5-Years
-22%
CAGR 10-Years
-15%
Alkermes Plc
NASDAQ:ALKS
Net Income (Common)
$339.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amarin Corporation PLC
NASDAQ:AMRN
Net Income (Common)
-$86.6m
CAGR 3-Years
2%
CAGR 5-Years
-40%
CAGR 10-Years
5%
M
Mural Oncology PLC
NASDAQ:MURA
Net Income (Common)
-$128.5m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Prothena Corporation PLC
Glance View

Market Cap
555.5m USD
Industry
Biotechnology

Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.

PRTA Intrinsic Value
7.7 USD
Overvaluation 25%
Intrinsic Value
Price

See Also

What is Prothena Corporation PLC's Net Income (Common)?
Net Income (Common)
-280.5m USD

Based on the financial report for Sep 30, 2025, Prothena Corporation PLC's Net Income (Common) amounts to -280.5m USD.

What is Prothena Corporation PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-15%

Over the last year, the Net Income (Common) growth was -113%. The average annual Net Income (Common) growth rates for Prothena Corporation PLC have been -21% over the past three years , -22% over the past five years , and -15% over the past ten years .

Back to Top